{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:12:26Z","timestamp":1779145946101,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH\/NIA K23AG082727"],"award-info":[{"award-number":["NIH\/NIA K23AG082727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["VA HSR IIR 20-256"],"award-info":[{"award-number":["VA HSR IIR 20-256"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-026-00642-y","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T10:57:15Z","timestamp":1775905035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment courses after anti-TNF de-escalation in older adults with rheumatoid arthritis: a medicare cohort study"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6402-6563","authenticated-orcid":false,"given":"Jiha","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Martindale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Una E.","family":"Makris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie P. W.","family":"Bynum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"10391","key":"642_CR1","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","volume":"401","author":"N Conrad","year":"2023","unstructured":"Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878\u201390.","journal-title":"Lancet"},{"key":"642_CR2","doi-asserted-by":"crossref","unstructured":"Chen C-I, Wang L, Wei W, Yuce H, Phillips K. Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. Rheumatol Adv Pract. 2018;2(1).","DOI":"10.1093\/rap\/rky005"},{"issue":"3","key":"642_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/mr\/roab087","volume":"32","author":"T Sugihara","year":"2022","unstructured":"Sugihara T. Treatment strategies for elderly-onset rheumatoid arthritis in the new era. Mod Rheumatol. 2022;32(3):493\u20139.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"642_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-022-02883-x","volume":"24","author":"W Fukuda","year":"2022","unstructured":"Fukuda W, Kadoya M, Omoto A, Yanagida T, Isoda Y, Sunaga A, et al. Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020. Arthritis Res therapy. 2022;24(1):190.","journal-title":"Arthritis Res therapy"},{"issue":"6","key":"642_CR5","doi-asserted-by":"publisher","first-page":"102528","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmun rev. 2020;19(6):102528.","journal-title":"Autoimmun rev"},{"issue":"9990","key":"642_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet (London England). 2015;386(9990):258\u201365.","journal-title":"Lancet (London England)"},{"key":"642_CR7","doi-asserted-by":"crossref","unstructured":"Uchida T, Iwamoto N, Fukui S, Morimoto S, Aramaki T, Shomura F, et al. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study. Rheumatology. 2023.","DOI":"10.1093\/rheumatology\/kead079"},{"issue":"8","key":"642_CR8","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/acr.25117","volume":"75","author":"BR England","year":"2023","unstructured":"England BR, Smith BJ, Baker NA, Barton JL, Oatis CA, Guyatt G, et al. 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis. Arthritis Care Res. 2023;75(8):1603\u201315.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"642_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"642_CR10","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res"},{"issue":"12","key":"642_CR11","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/acr2.11503","volume":"4","author":"J Lee","year":"2022","unstructured":"Lee J, Singh N, Gray SL, Makris UE. Optimizing Medication Use in Older Adults With Rheumatic Musculoskeletal Diseases: Deprescribing as an Approach When Less May Be More. ACR open Rheumatol. 2022;4(12):1031\u201341.","journal-title":"ACR open Rheumatol"},{"key":"642_CR12","doi-asserted-by":"crossref","unstructured":"Ouellet GM, Ouellet JA, Tinetti ME. Principle of rational prescribing and deprescribing in older adults with multiple chronic conditions. 2018;9(11):639\u201352.","DOI":"10.1177\/2042098618791371"},{"issue":"8","key":"642_CR13","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","volume":"75","author":"G Schett","year":"2016","unstructured":"Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428\u201337.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"642_CR14","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.clinthera.2013.09.015","volume":"35","author":"I Navarro-Mill\u00e1n","year":"2013","unstructured":"Navarro-Mill\u00e1n I, Sattui SE, Curtis JR. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther. 2013;35(11):1850\u2013e611.","journal-title":"Clin Ther"},{"issue":"6","key":"642_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.semarthrit.2018.10.017","volume":"48","author":"A Palmowski","year":"2019","unstructured":"Palmowski A, Buttgereit T, Palmowski Y, Nielsen SM, Boers M, Christensen R, et al. Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. Semin Arthritis Rheum. 2019;48(6):983\u20139.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"642_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40266-024-01125-w","volume":"41","author":"J Lee","year":"2024","unstructured":"Lee J, Kumar N, Kabeto M, Galecki A, Chang CH, Singh N, et al. Prevalence and Factors Associated with De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis: A Medicare Claims-Based Observational Study. Drugs Aging. 2024;41(7):601\u201313.","journal-title":"Drugs Aging"},{"issue":"19","key":"642_CR17","first-page":"1781","volume":"371","author":"P Emery","year":"2014","unstructured":"Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained Remission Etanercept Tapering Early Rheumatoid Arthritis. 2014;371(19):1781\u201392.","journal-title":"Sustained Remission Etanercept Tapering Early Rheumatoid Arthritis"},{"issue":"2","key":"642_CR18","doi-asserted-by":"publisher","first-page":"e000474","DOI":"10.1136\/rmdopen-2017-000474","volume":"3","author":"J Sigaux","year":"2017","unstructured":"Sigaux J, Bailly F, Hajage D, Mariette X, Morel J, Gandjbakhch F, et al. Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial. RMD open. 2017;3(2):e000474.","journal-title":"RMD open"},{"issue":"1","key":"642_CR19","doi-asserted-by":"publisher","first-page":"e0226754","DOI":"10.1371\/journal.pone.0226754","volume":"15","author":"B Birkner","year":"2020","unstructured":"Birkner B, Rech J, Stargardt T. Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. PLoS ONE. 2020;15(1):e0226754.","journal-title":"PLoS ONE"},{"issue":"12","key":"642_CR20","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2020-217528","volume":"79","author":"E van Mulligen","year":"2020","unstructured":"van Mulligen E, Weel AE, Kuijper TM, Denissen N, Gerards AH, de Jager MH, et al. Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial. Ann Rheum Dis. 2020;79(12):1550\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"642_CR21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/1744666X.2020.1686976","volume":"15","author":"G Cavalli","year":"2019","unstructured":"Cavalli G, Favalli EG. Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15(12):1313\u201322.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"642_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573\u20137.","journal-title":"Ann Intern Med"},{"issue":"11","key":"642_CR23","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/acr.22055","volume":"65","author":"J Zhang","year":"2013","unstructured":"Zhang J, Xie F, Delzell E, Chen L, Kilgore ML, Yun H, et al. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res. 2013;65(11):1743\u201351.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"642_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/art.22890","volume":"57","author":"G Schmajuk","year":"2007","unstructured":"Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007;57(6):928\u201334.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"642_CR25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/acr.23533","volume":"70","author":"JR Curtis","year":"2018","unstructured":"Curtis JR, Xie F, Chen L, Greenberg JD, Zhang J. Evaluation of a methodologic approach to define an inception cohort of rheumatoid arthritis patients using administrative data. Arthritis Care Res. 2018;70(10):1541\u20135.","journal-title":"Arthritis Care Res"},{"issue":"suppl 9","key":"642_CR26","first-page":"2024","volume":"76","author":"J Li","year":"2024","unstructured":"Li J SG. J <>Yazdany 2024 Evolution of rheumatoid arthritis pharmacotherapy: a ten-year analysis of biologic and targeted synthetic DMARD use and its predictors in a national sample of rheumatology practices. Arthritis Rheumatol 76 suppl 9 2024 [abstract].","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"642_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/pds.5157","volume":"30","author":"MM Ward","year":"2021","unstructured":"Ward MM. Accuracy of diagnoses of inflammatory arthritis in administrative hospitalization databases. Pharmacoepidemiol Drug Saf. 2021;30(2):257\u201365.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"642_CR28","doi-asserted-by":"publisher","first-page":"e243964","DOI":"10.1001\/jamahealthforum.2024.3964","volume":"5","author":"BN Rome","year":"2024","unstructured":"Rome BN, Bhaskar A, Kesselheim AS. Use, spending, and prices of adalimumab following biosimilar competition. JAMA Health Forum. 2024;5(12):e243964.","journal-title":"JAMA Health Forum"},{"key":"642_CR29","unstructured":"US Food and Drug Administration. Biosimilar product information. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"issue":"2","key":"642_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jgs.19280","volume":"73","author":"S Dublin","year":"2025","unstructured":"Dublin S, Albertson-Junkans L, Pham Nguyen TP, Pavon JM, Hastings SN, Maciejewski ML, et al. Defining key deprescribing measures from electronic health data: A multisite data harmonization project. J Am Geriatr Soc. 2025;73(2):399\u2013410.","journal-title":"J Am Geriatr Soc"},{"key":"642_CR31","doi-asserted-by":"crossref","unstructured":"Wang Y, Wilson DL, Fernandes D, Adkins LE, Bantad A, Copacia C, et al. Deprescribing strategies for opioids and benzodiazepines with emphasis on concurrent use: a scoping review. J Clin Med. 2023;12(5).","DOI":"10.3390\/jcm12051788"},{"key":"642_CR32","doi-asserted-by":"crossref","unstructured":"Almayali AAH, Boers M, Hartman L, Opris D, Bos R, Kok MR, et al. Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial. 2023:ard-2023-223977.","DOI":"10.1136\/ard-2023-223977"},{"key":"642_CR33","doi-asserted-by":"crossref","unstructured":"Gul H, Harnden K, Saleem B. Defining the optimal strategies for achieving drug-free remission in rheumatoid arthritis: a narrative review. Healthc (Basel Switzerland). 2021;9(12).","DOI":"10.3390\/healthcare9121726"},{"issue":"9","key":"642_CR34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/annrheumdis-2020-217485","volume":"79","author":"E van Mulligen","year":"2020","unstructured":"van Mulligen E, Weel AE, Hazes JM, van der Helm-van Mil A, de Jong PHP. Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial. Ann Rheum Dis. 2020;79(9):1174\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"642_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8\u201327.","journal-title":"Med Care"},{"key":"642_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fmed.2018.00039","volume":"5","author":"F Aslam","year":"2018","unstructured":"Aslam F, Khan NA. Tools for the Assessment of Comorbidity Burden in Rheumatoid Arthritis. Front Med. 2018;5:39.","journal-title":"Front Med"},{"issue":"1","key":"642_CR37","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13075-023-03199-0","volume":"25","author":"MM Ward","year":"2023","unstructured":"Ward MM, Madanchi N, Yazdanyar A, Shah NR, Constantinescu F. Prevalence and predictors of sustained remission\/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review. Arthritis Res therapy. 2023;25(1):222.","journal-title":"Arthritis Res therapy"},{"issue":"12","key":"642_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/acr2.11625","volume":"5","author":"J Lee","year":"2023","unstructured":"Lee J, Martindale J, Makris UE, Singh N, Yung R, Bynum JPW. Initiation of Disease-Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late-Onset Rheumatoid Arthritis. ACR open Rheumatol. 2023;5(12):694\u2013700.","journal-title":"ACR open Rheumatol"},{"issue":"1","key":"642_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10067-016-3490-8","volume":"36","author":"A Lenert","year":"2017","unstructured":"Lenert A, Lenert P. Tapering biologics in rheumatoid arthritis: a pragmatic approach for clinical practice. Clin Rheumatol. 2017;36(1):1\u20138.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"642_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/msc.1404","volume":"17","author":"LK Stamp","year":"2019","unstructured":"Stamp LK, Chan SJ, Marra C, Helme C, Treharne GJ. Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. Musculoskelet Care. 2019;17(3):161\u20139.","journal-title":"Musculoskelet Care"},{"issue":"2","key":"642_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/BOR.0000000000000782","volume":"33","author":"K Yip","year":"2021","unstructured":"Yip K, Navarro-Mill\u00e1n I. Racial, ethnic, and healthcare disparities in rheumatoid arthritis. Curr Opin Rheumatol. 2021;33(2):117\u201321.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"642_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MLR.0b013e31818af829","volume":"47","author":"F Constantinescu","year":"2009","unstructured":"Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47(3):350\u20135.","journal-title":"Med Care"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00642-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00642-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:44:48Z","timestamp":1779144288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41927-026-00642-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00642-y","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the University of Michigan Institutional Review Board, which granted a waiver of informed consent because the research involved secondary analysis of de-identified Medicare administrative claims data collected during routine clinical care and posed minimal risk to participants. The study was conducted in accordance with applicable federal regulations for the protection of human subjects (45 CFR 46, Common Rule) and relevant data use and privacy requirements of the Centers for Medicare & Medicaid Services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}